The Biotech Growth Trust (BIOG) is managed by Geoff Hsu and Richard Klemm at OrbiMed Capital, one of the leading global healthcare asset managers. The year 2018 proved to be tough for the trust’s performance as biotech companies delivering negative news were heavily penalised, while those delivering good news went unrewarded. However, the managers are optimistic about BIOG’s prospects. They cite a rich industry innovation pipeline that includes a series of technologies with multi-
15 Feb 2019
The Biotech Growth Trust - Industry backdrop remains favourable
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The Biotech Growth Trust - Industry backdrop remains favourable
Biotech Growth Trust PLC (BIOG:LON) | 928 -102.1 (-1.2%) | Mkt Cap: 310.9m
- Published:
15 Feb 2019 -
Author:
Mel Jenner -
Pages:
9
The Biotech Growth Trust (BIOG) is managed by Geoff Hsu and Richard Klemm at OrbiMed Capital, one of the leading global healthcare asset managers. The year 2018 proved to be tough for the trust’s performance as biotech companies delivering negative news were heavily penalised, while those delivering good news went unrewarded. However, the managers are optimistic about BIOG’s prospects. They cite a rich industry innovation pipeline that includes a series of technologies with multi-